Pharmafile Logo
Pharmafocus logo
Advanced Search
30562517863_f4ff8e801a_b

Conservatives pledge to invest in preventing and curing disease in election manifesto

November 26, 2019
Manufacturing and Production Boris Johnson, Conservative Party, Election 2019, Tories NHS, Tory Manifesto

Prime Minister Boris Johnson launched the Conservative Party’s manifesto on Sunday, promising to invest more into research to prevent and …

News

The coming age of biosimilars

November 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma

With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …

Feature
m-mansuri_370x250px

Sanofi’s head of strategy and business development to retire amid company review

November 25, 2019
Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …

News

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019
Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …

News
fdaoutsideweb

FDA fast-tracks psilocybin treatment for major depressive disorder

November 25, 2019
Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin

The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …

News
novartis_outside_1

Novartis acquires The Medicines Company in a deal worth $9.7 billion

November 25, 2019
Sales and Marketing Novartis, The Medicines Company, pharma

Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …

News
roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News
uk

Scotland leading the UK in life science start-up growth, report reveals

November 20, 2019
Research and Development, Sales and Marketing BioCity, UK, biotech, pharma

A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …

News
lilly_building_with_american_flag_web

Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created

November 20, 2019
Manufacturing and Production, Research and Development Eli Lilly, US, pharma

Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center …

News
merck-keytruda

Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo

November 20, 2019
Research and Development, Sales and Marketing Cancer, keytruda, pharma

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …

News
allergan

Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3

November 20, 2019
Research and Development Allergan, pharma, ubrogepant

Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …

News
darzalex-product-shot---100mg-vial-2-hr

European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

November 20, 2019
Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …

News
shutterstock_138095450

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019
Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …

News
amgen_flag

Amgen poised to cut 172 positions across US, including California HQ

November 19, 2019
Manufacturing and Production Amgen, US, pharma

As revealed in correspondence with the California Employment Development Department, Amgen plans to axe 172 staff positions across the US, …

News
shutterstock

Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3

November 19, 2019
Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat

MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …

News
vertex-headquarters

Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients

November 19, 2019
Manufacturing and Production, Research and Development Vertex, crispr, pharma

Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety and efficacy of the investigational …

News
alk_logo_32_nodith

Alkermes snaps up Rodin Therapeutics for a potential $950 million

November 19, 2019
Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma

Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …

News
capture

Bringing the clinical trial home

November 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, research

Clinical trials are the backbone of healthcare and drug research, but many key patient populations have in the past been …

Feature

Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023

November 18, 2019
Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,   …

News
mayzent

EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis

November 18, 2019
Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026